Testing the drug pumitamig in adults whose glioblastoma came back
Original title: A Clinical Trial Testing the Safety of the Investigational Drug Pumitamig (BNT327) and How Well it Works in Patients With Recurrent Glioblastoma
How far along is this research?
This is a trial that is enrolling or has been updated. It is not a finding yet.
This is a middle stage trial, so the drug is still being tested in people.
Status: Recruiting. It is looking for patients now. Talk to your care team about whether it fits you.
The trial team last updated this record on . Always check the trial page for the latest.
The short version
This study tests a drug called pumitamig in adults whose brain tumor has come back.
Who this trial is for. This trial is for adults whose glioblastoma: A glioma that is given grade 4. Grade 4 is the highest grade there is. The tumor grows fast. Treatment usually starts soon after it is found. It often means surgery, and then radiation and chemotherapy. See the glossary came back after radiation and temozolomide: A chemotherapy taken as a capsule, used for some brain tumors. Your team checks your blood counts while you are on it. See the glossary. It tests how safe the drug pumitamig is and how well it works.
Where it stands. This trial has not reported results. It is measuring how safe the drug is and whether it helps. The answer is not in yet.
What this means, and what it doesn't
What it could mean: We do not know yet if this drug helps. Someone who fits this trial could ask their care team about it.
What it doesn't mean: This does not mean the drug works. A trial is a test, not proven treatment. Joining one is not a promise of help. It is not a cure.
Source: ClinicalTrials.gov, October 28, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.